

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Trotter, et al.

Application
No.: 10/572,341

Filed: March 17, 2006

For: QUINAZOLINE POTASSIUM CHANNEL INHIBITORS

Art Unit: 1626

Examiner: To be
assigned

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97**

Sir:

In compliance with 37 C.F.R. 1.97, submitted on the attached form PTO/SB/08a is a list of patents, publications, applications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication, application or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

Pursuant to 37 C.F.R. 1.98(a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

Applicants respectfully request the Examiner initial the attached form PTO/SB/08a after reviewing the pertinence of each reference.

Any fees required in connection with this submission may be charged to Merck Deposit
Account No. 13-2755.

Respectfully submitted,

Heidi M. Struse

By: Heidi M. Struse
Attorney for Applicant(s)
Reg. No. 50,288

MERCK & CO., INC.
P.O. Box 2000
Rahway, N.J. 07065-0907
(732) 594-0238

Date: July 10 2009